1. Olmesartan Medoxomil
A Review of its Use in the Management of Hypertension
Lesley J. Scott and Paul L. McCormack. Drugs 2008; 68 (9): 1239-1272
Studies in monkeys and rabbits suggest that olmesartan medoxomil may inhibit or reverse the ents formation of atherosclerotic lesions (table II). Although olmesartan medoxomil and atenolol reduced carotid intima media thickness (a surrogate marker of atherosclerotic plaque formation) to a similar extent in hypertensive patients with atherosclerosis, olmesartan medoxomil, but not atenolol, reduced the volume of large plaques, indicating a potential anti-atheroslcerotic effect independent of BP lowering.
2. Olmesartan Medoxomil/Amlodipine
Mark Sanford and Susan J. Keam. Drugs 2009; 69 (6): 717-729
Olmesartan medoxomil/amlodipine (Sevikar®), a fixed-dose formulation of the angiotensin II type 1 (AT1) receptor blocker olmesartan medoxomil and the dihydropyridine CCB amlodipine, is approved in several European countries for once-daily administration in patients with essential hypertension who have not responded adequately to monotherapy with olmesartan medoxomil or amlodipine, or who are receiving separate tablets as combination therapy. In the US, the fixed-dose formulation is marketed as AzorTM and is approved for the treatment of hypertension, alone or with other antihypertensive agents. This article focuses, from an EU perspective, on efficacy and tolerability studies of olmesartan medoxomil/amlodipine in patients with hypertension, with a brief overview of its pharmacological properties. Medical literature on the use of olmesartan medoxomil/amlodipine in hypertension was identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Wolters Kluwer Health j Adis). Additional references were identified fromthe reference lists of published articles.
3. Efficacy and Tolerability of Olmesartan Medoxomil Combined with Amlodipine in Patients with Moderate to Severe Hypertension after Amlodipine Monotherapy
A Randomized, Double-Blind, Parallel-Group, Multicentre Study. Clin Drug Invest 2009; 29 (1): 11-25
Olmesartan medoxomil/amlodipine 40/5 mg produced the most rapid lowering of SBP and DBP. A difference in mean SeSBP reduction of 1.4 mmHg was evident between the olmesartan medoxomil/amlodipine 40/5 mg group and the olmesartan medoxomil/amlodipine 20/5 mg group at week 16, although the magnitude of SeDBP reduction was similar in these groups at week 16 (–9.6 mmHg and–9.5 mmHg, respectively).
Significantly higher proportions of patients reached the BP goal with olmesartan medoxomil/ amlodipine 5 mg combination regimens compared with the placebo/amlodipine 5 mg regimen. At the end of 8 weeks of double-blind therapy (week 16), 51% and 54% of patients treated with olmesartan medoxomil/amlodipine 40/5 mg and olmesartan medoxomil/amlodipine 20/5 mg, respectively, reached BP goal (p < 0.0001 vs 30% [55/184] of patients at goal treated with placebo/amlodipine 5 mg). Thirty-nine percent of patients treated with olmesartan medoxomil/amlodipine 10/5 mg reached BP goal (p = 0.0286 vs placebo/amlodipine 5 mg).